Oncotarget

Research Papers:

Long non-coding RNA PTENP1 interacts with miR-193a-3p to suppress cell migration and invasion through the PTEN pathway in hepatocellular carcinoma

Yu-Yuan Qian, Kun Li, Quan-Yan Liu _ and Zhi-Su Liu

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:107859-107869. https://doi.org/10.18632/oncotarget.22305

Metrics: PDF 1435 views  |   HTML 3126 views  |   ?  


Abstract

Yu-Yuan Qian1,*, Kun Li1,*, Quan-Yan Liu1 and Zhi-Su Liu1

1Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

*These authors have contributed equally to this work

Correspondence to:

Quan-Yan Liu, email: [email protected]

Zhi-Su Liu, email: [email protected]

Keywords: hepatocellular carcinoma; PTENP1; miR-193a-3p; PTEN; ceRNA

Received: August 30, 2017    Accepted: October 13, 2017    Published: November 06, 2017

ABSTRACT

Long non-coding RNA PTENP1, the pseudogene of PTEN tumor suppressor, was previously reported to be a tumour suppressor in some cancer types. However, the precise effects mediated by PTENP1 transcripts within intricate regulatory networks involving molecular interactions with PTEN and tumorigenicity in hepatocellular carcinoma (HCC) remains elusive. Here, we identify the critical biological functions of PTENP1 and discuss whether PTENP1 could directly interact with miR-193a-3p to affect the progression of HCC both in vitro and in vivo. We demonstrated that PTENP1 level in the HCC tissues was significantly lower compared with those in the adjacent normal tissues. And PTENP1 was able to repress cell invasion, metastasis, and proliferation capacity in HCC cell lines. The overexpression of PTENP1 inhibited HCC growth both in vitro and in vivo. There were a binding sequence and direct interaction between PTENP1 and miR-193a-3p. PTENP1 as an endogenous sponge interacted with miR-193a-3p, leading to regulate the downstream PTEN/Akt pathway.

These results suggested that PTENP1 with its suppression effect might serve as novel biomarkers and potent therapeutic strategies in HCC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22305